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Results: We show the different Robotic surgical steps of the
pancreatoduodenectomy which includes the tumor resection
and robotic surgical reconstructions (biliary, pancreatic and
intestinal anastomosis).
Conclusion: This video shows the efficacy and feasibility of
robotic pancreatic surgery providing a three dimensional
imaging, a greater instrumental movement and tremor filter-
ing of the surgeon, thus reducing the minimally invasive
surgery related complexity.
VB.02 SYNCHRONOUS TOTAL
LAPAROSCOPIC RIGHT HEPATECTOMY
AND RIGHT HEMICOLECTOMY
S. Jayaraman
University Of Toronto, Toronto, ON
Synchronous resection of primary colon cancer and liver
metastases has been shown to be safe and effective in
selected cases. This video details the presentation of an
asymptomatic patient with a colon cancer originating in the
cecum as well as an isolated hepatic metastasis near the
bifurcation of the right anterior and posterior inflow pedicles.
In order to obtain total oncologic clearance, a right hepatec-
tomy and right hemicolectomy was indicated. The operation
begins with the hepatectomy being performed laparoscopi-
cally with out the aid of open or hand ports. Upon completion
of the hepatectomy, the right liver specimen is placed in
a large bag in the right upper quadrant. The laparoscopic
right hemicolectomy ensues including a medial approach
and high ligation of the ileocolic pedicle. Subsequently an
intracorporeal laparoscopic ileocolic anastomosis is per-
formed. Both the liver and colon specimen are removed
through a Pfannensteil incision. The final pathology showed
a pT3N1M1 colon cancer with all margins negative. The
patient was discharged on the ninth postoperative day with an
uneventful hospitalization. In one year follow up and after
completion of adjuvant therapy, there is no evidence of
recurrence.
VB.03 NEAR INFRARRED
TECHNOLOGY GIVES A NEW TOOL TO
THE SURGEONS TO IDENTIFY BILIARY
ANATOMY
F. Dip, M. Roy, C. Simpfendorfer, E. Lomenzo,
S. Szomstein and R. Rosenthal
Cleveland Clinic Florida, Weston, FLORIDA
Introduction: Fluorescence-guided surgery is a novel tech-
nology that could facilitate the recognition of bile duct struc-
tures. Using adequate fluorescent dye and appropriate
laparoscopic equipment, critical structures can be identified.
Method: The procedure begins with administration of a
single dose of 0.05 mg/kg of indocyanine green one hour
prior to surgery. A Storz® xenon light source and laparoscope
with a charge-coupled device that filters out light wave-
lengths except 830 nm with a specific 780 nm infrared light
source is used intraoperatively. The light of the laparoscope
can be easily changed to the infrared view using a pedal.
When illuminated by infrared light, the dye manifests fluo-
rescence. Abdominal inspection with standard trocar place-
ment is performed. The fluorescence system is then activated
using the pedal. Since the dye is excreted exclusively by the
liver it creates the biliary structures can be identified because
of fluorescence.
Results: This video demonstrates the feasibility of the tech-
nique using indocyanin green as described above. Visualiza-
tion of the cystic duct, hepatic ducts, accessory ducts and
main bile duct is shown using fluorescence.
Conclusion: Near infrared technology seems to be a fea-
sible and easy method to delineate the biliary tree anatomy in
real time.
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O-G.01 EARLY IDENTIFICATION OF
PATIENTS AT INCREASED RISK FOR
HEPATIC INSUFFICIENCY,
COMPLICATIONS, AND MORTALITY
AFTER MAJOR HEPATECTOMY
J. W. Etra1, M. H. Squires1, S. B. Fisher1, D. R. Rutz1,
B. Martin1, D. A. Kooby1, K. Cardona1, J. M. Sarmiento2,
C. A. Staley1, S. K. Maithel1 and M. C. Russell1
1Department Of Surgery, Division Of Surgical Oncology,
Winship Cancer Institute, Emory University, Atlanta,
GEORGIA; 2Department Of Surgery, Division Of General
And Gastrointestinal Surgery, Emory University, Atlanta,
GEORGIA
Background: A postoperative bilirubin >7 mg/dL is an
accepted definition of postoperative hepatic insufficiency
(PHI), as it is associated with increased complications and
mortality after hepatectomy. Early recognition of these
patients at increased risk may affect treatment strategy. Our
aim was to identify a surrogate marker for PHI early in the
postoperative course.
Methods: A single institution database of patients undergo-
ing major hepatectomy (≥3 segments) from 2000–2012 was
retrospectively reviewed. Preoperative, intraoperative, and
early postoperative factors were assessed for association with
any complications, major complications (Clavien Grade III-
V), and 90-day mortality.
Results: 607 patients undergoing major hepatic resection,
excluding bile duct reconstruction, were identified. Post-
operative complications and major complications occurred in
352(58%) and 136(22%) patients. 90-day mortality was 4%.
A postoperative day 3 (POD3) total bilirubin ≥3 mg/dL was
significantly (p < 0.001) associated with increased risk of
post-operative complications (76% vs 54%), major compli-
cations (46% vs 18%), and 90-day mortality (16% vs 2%;
Figure I). This association persisted on multivariate regres-
sion analysis for all 3 endpoints: any complications
(HR:1.98, 95%CI:1.10–3.54,p = 0.022), major complica-
tions (HR:3.18, 95%CI:1.90–5.32,p < 0.001), and 90-day
mortality (HR:8.11, 95%CI:3.00–21.92,p < 0.001; Table I).
A POD3 bilirubin ≥3 was the only early perioperative factor
associated with the development of a postoperative total bili-
Abstracts 45
© 2014 The Authors
HPB © 2014 Americas Hepato-Pancreato-Biliary AssociationHPB 2014, 16 (Suppl. 1), 1–99
rubin >7 and/or ascites on multivariate analysis (HR:7.81,
95%CI:3.74–16.31,p < 0.001).
Conclusion: Total bilirubin ≥3 mg/dL on POD3 after major
hepatectomy is significantly associated with increased com-
plications, major complications, and 90-day mortality. This
marker may serve as a predictor in the early postoperative
course for hepatic insufficiency, given its strong association
with adverse outcomes and increased mortality.
O-G.02 EFFECT OF OBESITY ON
PERIOPERATIVE OUTCOMES
FOLLOWING LAPAROSCOPIC
HEPATECTOMY
S. Lee, A. Hauch, E. Kane, E. Kandil and J. Buell
Tulane Transplant Institute, Tulane University School Of
Medicine, New Orleans, LA
Background: Laparoscopic hepatectomy has become
increasingly more accepted in the treatment of liver tumors in
selected patients. Whether obese patients would benefit from
laparoscopic hepatectomy has not been investigated. This
study evaluates the effect of obesity on perioperative out-
comes following laparoscopic hepatectomy.
Methods: Retrospective review of 382 consecutive patients
undergoing laparoscopic hepatectomy. Patients were divided
into three weight classes: normal, overweight (BMI ≥25),
and obese (BMI ≥30). Comparisons and analysis were made
against the normal group on preoperative factors, operative
variables, and perioperative outcomes.
Results: There were 382 total patients, with 76 (20%)
normal, 204 (53.4%) overweight, and 102 (23%) obese. The
groups were equivalent with respect to age, presence of cir-
rhosis, segments resected, while the mean ASA score was
higher in the obese group. EBL and OR time were greater for
the overweight and obese groups, however only significant
for the overweight group. Length of stay and post-operative
complications were also statistically similar between groups.
The multivariate model of factors significantly correlated
with complications included weight class, ASA score, blood
loss, and number of segments resected. In the multivariate
model, morbid obesity (BMI >35) was significantly associ-
ated with complications (OR 3.125; p = 0.033), while BMI
<35 was not significant (OR 0.973; p = 0.945).
Conclusion: Similar to many open operations, weight may
be associated with a slightly longer operating time and
greater blood loss in laparoscopic hepatectomy. Overall com-
plications as well as length of stay are similar for overweight
and obese patients compared to normal BMI patients.
O-G.03 MORTALITY IN HEPATECTOMY:
MODEL FOR END-STAGE LIVER
DISEASE (MELD) AS A PREDICTOR FOR
DEATH USING THE NATIONAL
SURGICAL QUALITY IMPROVEMENT
PROGRAM (NSQIP)
S. W. Ross, B. Oommen, M. Kim, V. A. Augenstein,
A. L. Walter, B. T. Heniford, D. A. Iannitti, J. B. Martinie
and R. Z. Swan
Carolinas Medical Center, Department Of General
Surgery, Charlotte, NC
Introduction: Current literature is mixed on the predictive
value of MELD score for mortality in hepatectomy. We
hypothesized that MELD will independently correlate with
30-day mortality in patients undergoing hepatic resection.
Methods: The American College of Surgeons NSQIP data-
base was queried for hepatectomy. Original MELD, UNOS
modification MELD(uMELD), integrated MELD(iMELD),
and sodium corrected MELD(MELD-Na) were also calcu-
lated. Demographics, comorbidities, operative details, and
patient outcomes were compared using standard statistical
tests and examined by MELD type. Mortality was analyzed
using logistic regression and the MELD types were com-
pared using receiver operating curves (ROC).
Results: There were 11,933 hepatectomies from 2005–
2011: 7,519 partial; 2,104 right; 1,210 left; and 1,100
trisegmentectomy. Demographics and mean MELD scores:
age 58.7 ± 13.4, BMI 28.0 ± 6.3 kg/m2, MELD 3.4 ± 4.8,
uMELD 7.9 ± 2.5, MELD-Na 8.2 + 2.9, and iMELD
31.2 + 5.0. 51.8% were male and 82.5% were Caucasian.
Mean length of stay was 8.4 ± 22.0 days, and there were 275
deaths(2.4%). 30-day mortality rates by uMELD strata were:
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0–9(1.8%), 10–19(6.9%), 20–29(15.4%), 30 + (25.0%); and
on bivariate analysis all MELD types were associated with
higher mortality (p < 0.001). All meld types were indepen-
dently associated with mortality (p < 0.001) and uMELD had
the largest effect size (OR: 1.20, 1.17–1.24). iMELD had the
narrowest confidence interval (OR: 1.18, 1.15–1.21) and
largest area under the ROC.
Conclusion: Our study shows that hepatectomy patients
with higher MELD scores have increasing rates of 30-day
mortality. For every point increase in uMELD there is a 20%
increase in mortality risk. Additionally, iMELD has the best
predictive characteristics for mortality when compared to
other MELD scores.
O-G.04 ENUCLEATION OF HEPATIC
NEUROENDOCRINE TUMOR
METASTASES: A VALUABLE ADJUNCT
TO SURGICAL CYTOREDUCTION
N. N. Nissen1, V. G. Menon1, E. M. Wolin2, R. Yu2,
S. D. Colquhoun1
1Hepatobiliary And Pancreatic Surgery, Cedars-Sinai
Medical Center, Los Angeles, CA; 2Carcinoid And
Neuroendocrine Tumor Program, Cedars-Sinai Medical
Center, Los Angeles, CA
Objective: Hepatic neuroendocrine tumor (NET) metasta-
ses are often treated with cytoreductive surgery. The unique
nature of these tumors may allow parenchymal preservation
using the technique of enucleation, but this approach has not
been systematically evaluated.
Design: We reviewed our surgical experience in 100 con-
secutive patients with metastatic hepatic NETs between
2003–2013. Thirty-eight patients (38%) underwent planned
enucleation (ENUC) as a component of surgery and these
were compared to standard resection.
Results: ENUC was performed more commonly in recent
years, and was combined with anatomic hepatic resection in
20 patients (53%), tumor ablation in 14 (37%) and resection
of primary abdominal tumor in 25 patients (66%). Mean
number of lesions enucleated was 5 (range 1–26), and mean
size of the largest enucleated lesion was 5.6 cm (range
1–19 cm). Laparoscopic ENUC was completed in 4 patients
(11%). There was no mortality. Complications of Clavien
grade 3 or more occurred in 22%, including 14% rate of bile
leak, similar to patients undergoing standard resection. The
ability to achieve maximal cytoreduction (>90% of tumor
removed) was greater in the ENUC versus standard group
(79 vs. 47%, p = .0028). Also, fewer patients in the ENUC
group required additional hepatic therapy within 12 months
compared to standard group (16 vs. 34%, p = .03). Both
ENUC and standard groups showed excellent survival (92/
88% and 88/72%) at 1/3 years respectively.
Conclusion: Enucleation is a safe and effective tool in sur-
gical management of hepatic NETs. Patients treated with a
surgical strategy using this approach can often have near-
complete cytoreduction and are unlikely to need additional
hepatic therapies over the short term.
O-G.05 EXPRESSION LEVELS OF
INSULIN-LIKE GROWTH FACTORS AND
RECEPTORS IN HEPATOCELLULAR
CARCINOMA
Y. S. Chun1, M. Huang2 and L. Rink2
1Virginia Piper Cancer Institute, Minneapolis, MN; 2Fox
Chase Cancer Center, Philadelphia, PA
Introduction: The insulin-like growth factor (IGF) pathway
is implicated in the pathogenesis of hepatocellular carcinoma
(HCC) and may be particularly important in patients with
non-alcoholic fatty liver disease (NAFLD) and metabolic
syndrome, which is associated with insulin resistance and
increased levels of bioavailable IGF-1. The aim of this study
was to determine expression levels of IGFs and their recep-
tors in patient with NAFLD-associated HCC.
Methods: Tissue microarrays were constructed from
patients who underwent hepatectomy for HCC.
Immunohistochemistry was performed using antibodies for
IGF-1, IGF-2 and their receptors, IGF-1R and IGF-2R.
Slides were read by a pathologist blinded to clinical data.
Median follow-up was 26 months (range, 2–136 months).
Results: Among 27 patients with HCC, the most common
underlying liver diseases included NAFLD (n = 13, 48%),
hepatitis C (n = 7, 26%), and alcoholic hepatitis (n = 2, 7%).
Expression levels of IGFs and their receptors were not asso-
ciated with patients’ underlying liver disease. In all patients,
IGF-2 expression was upregulated in tumor and adjacent
non-tumorous liver. IGF-1 expression was low in adjacent
non-tumorous liver in 6 of 10 patients (60%) with cirrhosis,
compared to 2 of 17 patients (12%) without cirrhosis
(p = 0.008). Higher IGF-1 expression in adjacent liver rela-
tive to tumor was associated with significantly poorer median
survival of 22 months, compared to 72 months with equal or
lower IGF-1 expression in adjacent liver relative to tumor
(p = 0.006).
Conclusion: Our preliminary results demonstrate signifi-
cant associations between IGF-1 expression and liver cirrho-
sis and survival after resection in patients with HCC,
independent of their underlying liver disease.
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O-G.06 POSITIVE CROSSMATCH AND
THE ROLE OF DONOR SPECIFIC
ANTIBODY IN LIVER
TRANSPLANTATION
R. J. Lynch, N. Lysak, S. Perez, T. Roberts-Wilson,
R. A. Bray, H. M. Gebel and S. J. Knechtle
Emory Transplant Center, Atlanta, GA
Introduction: Although the importance of crossmatch and
donor specific antibody (DSA) is clear in renal transplanta-
tion, their utility is unproven in liver transplantation. Recent
studies have suggested that alloantibody could be implicated
in acute reperfusion injury, and may initiate or potentiate
graft rejection.
Methods: We performed a retrospective analysis of liver
transplants at our center from 2011–2013. Donor and recipi-
ent demographics, etiology of liver disease and graft
ischemic time were recorded. Histocompatibility data were
taken from a prospectively maintained database of
crossmatch and alloantibody titers. Patient outcome was
assessed through postoperative transaminase levels and inci-
dence of readmission, biliary complications, and hepatic
artery thrombosis. Histologically-confirmed rejection epi-
sodes were cataloged by type and severity.
Results: 174 patients were followed for 318 ± 157 days.
Immunosuppression consisted of calcineurin inhibitor,
mycophenolate mofitil ± steroids. 48 patients had a positive
crossmatch, of which 30 were found to be due to human
leukocyte antigens (HLA). Of these, 16 had high (>10,000
MESF) anti MHC Class I antibody titers, and 9 had high
MHC Class II titers. There were no significant demographic
differences between groups. 24 hour transaminase measure-
ments, as well as clinical complication rates, were similar.
Rejection-free survival was slightly better in the positive
crossmatch group, though this did not achieve statistical sig-
nificance (32% vs 19%, p 0.08, Figure 1).
Conclusion: Among liver transplant recipients, the presence
of a positive crossmatch is not associated with adverse clini-
cal or immunological outcomes. High titers of anti-donor
antibody did not predict tissue injury or rejection over
medium-term followup.
O-G.08 INTRAOPERATIVE
ULTRASOUND DURING RESECTION OF
COLORECTAL LIVER METASTASES:
IMPACT ON DETECTION OF LESIONS,
CHANGE IN SURGICAL STRATEGY AND
ACHIEVEMENT OF NEGATIVE
RESECTION MARGINS
S. A. Knowles1, K. P. Croome2 and
R. Hernandez-Alejandro1
1Division Of General Surgery, Western University ,
London, ONTARIO; 2Division Of Gastroenterologic And
General Surgery, Mayo Clinic, Rochester, MINNESOTA
Liver resections with negative margins improve survival
in patients with colorectal liver metastases (CRLM).
Intraoperative ultrasound (IOUS) is a valuable tool that can
potentially give information about lesions that ultimately
changes surgical strategy to ensure complete resection,
which subsequently improves disease free survival (DFS). A
retrospective chart review of patients who underwent a liver
resection for CRLM from 2009 to 2012 was performed in
order to determine the impact of IOUS. A total of 103
patients had a hepatic resection for CRLM. All of the patients
had a preoperative triphasic CT and/or MRI to assist with
operative planning. IOUS was performed in 72 cases. Surgi-
cal strategy changed in 31 (43.1%) cases with IOUS, com-
pared to three (9.7%) with no IOUS (p < 0.001) (Figure 1).
The most common reason for these changes was the location
of the lesion as visualized by IOUS (N = 18, 25.0%), fol-
lowed by detecting a new lesion not seen on preoperative
imaging (N = 12, 16.7%). A higher proportion of non-
anatomic liver resections were performed in the IOUS group
(N = 45, 62.5%) compared to the non-IOUS group (N = 11,
35.5%). Achieving a negative resection margin (R0 resec-
tion) was comparable between the two groups. However,
there was a trend toward improved DFS in the IOUS group.
Despite advances in preoperative imaging, IOUS still dem-
onstrates utility in detecting new lesions and giving novel
information about these lesions that ultimately changes the
operative plan, potentially improving DFS. It also assists
the surgeon in performing parenchymal-preserving liver
resections.
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O-G.09 NON-INVASIVE PREDICTION OF
SINUSOIDAL INJURY IN PATIENTS
TREATED WITH OXALIPLATIN FOR
COLORECTAL LIVER METASTASES
J. Urdzik1, T. Bjerner2, A. Wanders3, F. F. Duraj1,
U. Haglund1 and A. Norén
1Department Of Surgery, Uppsala University, Uppsala,
SWE; 2Department Of Radiology, Uppsala University,
Uppsala, SWE; 3Department Of Immunology, Genetics And
Pathology, Uppsala University, Uppsala, SWE
Introduction: Noninvasive methods to identify patients
with sinusoidal injury (SI) after oxaliplatin based therapies
for colorectal liver metastases (CRLM) have been proposed.
Predictive values of APRI score (aspartate aminotransferase
to platelets ratio index), spleen volume changes and portal
vein hemodynamic changes were compared.
Methods: APRI and magnetic resonance imaging
flowmetry measuring portal vein hemodynamics were esti-
mated the day before liver surgery in 29 patients. Spleen
volume changes were calculated from segmented spleen
volumes on CT or MR imaging before chemotherapy start
and the day before surgery. Resected non-tumorous liver
parenchyma was evaluated according to Complex Vascular
Injury score (≥3 was recognized as relevant SI).
Results: SI was observed in 6 of 29 patients. 5 of these 6
patients received oxaliplatin; however, the relation SI to
oxaliplatin was not significant. Patients with SI demonstrated
higher APRI score (p = 0.008), larger portal vein cross-
section area (AREA) (p = 0.041) and lower mean portal flow
velocity (VELO) (p = 0.016). VELO correlated with AREA
(r = -0.552). Spleen volume changes correlated with APRI
(r = 0.391) and AREA (r = 0.457), but did not change with
SI. Logistic regression identified APRI and VELO as the
only two independent predictors of SI. APRI ≥ 0.36 together
with VELO ≤14.35 cm/s predicts SI with 100% sensitivity
and 83% specificity, while area under receiver operating
characteristic curve was 0.920.
Conclusion: APRI combined with VELO can predict SI
with high accuracy. Identified APRI threshold value was the
same as in the previously published papers. Spleen volume
changes and other portal vein hemodynamics parameters
were less accurate in SI prediction.
O-G.10 PATIENT AND TUMOR BIOLOGY
PREDICT SURVIVAL BEYOND THE
MILAN CRITERIA IN LIVER
TRANSPLANTATION FOR
HEPATOCELLULAR CARCINOMA
A. Andreou, P. Neuhaus and D. Seehofer
Department Of General, Visceral And Transplant Surgery,
Charité Campus Virchow Klinikum, Berlin, BERLIN
Background: Milan criteria (MC) are currently the most estab-
lished selection tool for liver transplantation (LT) in patients with
hepatocellular carcinoma (HCC). Patients with HCC beyond MC
arenotconsideredforLTinmanycenters;however,LTmaybe the
only treatment able to prolong survival in these patients with
unresectable HCC. The aim of this study was to assess the role of
recipient age and tumor biology expressed by DNA-index in the
selection of HCC patients for LT.
Methods: Clinicopathological data of 364 patients with
HCC who underwent LT in a high-volume transplant center
between 1989 and 2010 were evaluated. Overall survival
(OS) was analyzed by tumor burden based on MC, patient
age and DNA-index.
Results: After a median follow-up of 78 months, the median
survival was 100 months. Factors associated with OS in
univariate analysis included MC, patient age, DNA-index
and α-fetoprotein-level. In multivariate analysis, HCC
beyond MC, DNA-index >1.5, and α-fetoprotein-level
>200 ng/mL independently predicted worse OS. When strati-
fying patients by both MC and age, patients younger than 60
years with HCC beyond MC had OS comparable to that of
older patients within MC (10-year-OS 32% vs. 37%,
P = .008, Figure1). Patients < 60 years old with HCC beyond
MC but DNA-index < 1.5 had excellent OS (Figure2), com-
parable to that of patients within MC.
Conclusions: Patients younger than 60 years may undergo
LT for HCC with favorable outcomes independently from
their tumor burden. Additional assessment of tumor biology
using DNA-index within this subset of patients can contrib-
ute to the selection of liver transplant candidates who may
derive the most long-term survival benefit beyond MC.
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O-G.11 A 20 YEAR REVIEW OF LIVER
TRANSPLANTATION: CHANGING
INDICATIONS OVER 2 DECADES
M. Doyle, N. Vachharajani, J. A. Lowell, S. Shenoy,
J. R. Wellen , Y. Lin and W. C. Chapman
Washington University School Of Medicine , St. Louis, MO
Introduction: Liver transplantation(OLT) has evolved over
the past 20 years becoming a successful treatment for liver
failure. Aim: We review our results with regard to indica-
tions, trends and failure.
Methods: Using a prospectively database, we reviewed
adult recipients undergoing OLT since 1993. Demographics,
indications and survival were determined, as well as an
analysis of graft loss and mortality.
Results: Between 1/1/1993 and 12/31/2012, 1283 adult
OLTs were performed. 37% (475/1283) transplants occurred
before 2003. 1-, 5-, 10-, and 20 yr patient survival was
88.8%, 75.9%, 62.5% and 39.4% (median 16.1 yrs). Median
graft survival was 14.5 yrs, with 30-day graft loss of 1.8%,
usually related to HAT and PNF. 30-day mortality was 4.2%
and was primarily due to bleeding or sepsis. Late deaths
(>10 yrs) were primarily related to cardiac, hepatorenal, non-
liver malignancy, or sepsis. Late graft loss was mainly due to
cholangiopathy, rejection, chronic graft dysfunction and
disease recurrence. 75 patients were retransplanted, with 1,
5- and 10-yr patient survival after retransplantation of 76.6%,
58.2% and 53.1%. OLT for cancer (35 vs 10.9%), HCV (43
vs31%) and NASH (7vs 0.9%) was more common in the
second decade (>2003) and less common for PBC/ PSC (8.4
vs22%)(p < 0.001). Extended criteria donors were more
likely to be used in the second decade (20.2% vs11.1%
p < .0001).
Conclusion: This 20 yr single center liver transplant
program demonstrates excellent long term patient survival
and outcomes. There has been a significant shift in the use of
transplantation for HCC, HCV, and NASH, in the last
10-year period.
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O-G.12 A SIMPLIFED FRAILTY INDEX
TO ACCURATELY PREDICT MORBIDITY
AND MORTALITY AFTER HEPATIC
RESECTION
L. M. Louwers, G. Schnickel and I. Rubinfeld
Henry Ford Health System, Detroit, MI
Background: Frailty has been established as an important
predictor of surgical outcomes. We hypothesized our modi-
fied frailty index (mFI) would be a helpful assessment for
serious morbidity and mortality among patients undergoing
hepatic resection.
Methods: The National Surgical Quality Improvement
Project (NSQIP) database was queried for all patients who
had liver resections from 2005–2011. A previously described
and validated mFI was calculated on the basis of NSQIP
variables. The impact of frailty on 30-day serious postopera-
tive morbidity (Clavien level 4, i.e. cardiac failure, respira-
tory failure, acute renal failure, sepsis, stroke, etc) and
mortality was evaluated. Data was analyzed using chi-
squared and multivariate logistic regression. Analysis was
performed using SPSS 21 software, with p < .05 defined as
significant.
Results: Within the 10,300 patients (6189 partial lobec-
tomy, 3094 lobectomy, 1017 extended hepatectomy), the
30-day Clavien 4 complication and mortality rates were 7.5%
(775/10300) and 2.3% (242/10300), respectively. Mean
(range) mFI was 0.12 (0–0.67) in the Clavien 4 complication
group and 0.13 (0–0.67) in the mortality group, versus 0.08
among patients who did not experience morbidity or mortal-
ity, p < 0.001 for both groups. Logistic regression using the
mFI with NSQIP variables of age, ASA score, wound class,
and emergency status demonstrated mFI was the strongest
predictor of Clavien 4 complications (OR 2.61, p = 0.003)
and mortality (OR 3.37, p = 0.022)
Conclusion: Frailty may be an important predictor of mor-
bidity and mortality among patients undergoing hepatic
resection. The mFI is a simple and accurate tool, based on
data collected in the patient history, to facilitate preoperative
risk assessment.
O-G.13 ASSOCIATING LIVER PARTITION
AND PORTAL VEIN LIGATION FOR
STAGED HEPATECTOMY (ALPPS)
VERSUS PORTAL VEIN EMBOLIZATION
IN THE MANAGEMENT OF
COLORECTAL LIVER METASTASES
R. Hernandez-Alejandro1 and K. P. Croome1,2
1Western University Canada, London, ONTARIO; 2Mayo
Clinic, Rochester, MN
Background: Meticulous selection of those patients that
can safely undergo the ALPPS procedure will be paramount
in order to minimise the morbidity and mortality associated
with the procedure.
Methods: A total of 10 consecutive patients undergoing the
ALPPS procedure and 15 patients undergoing portal vein
embolization (PVE) with planned resection for colorectal
liver metastases (CRLM) between the dates of May 1 2008
and May 1 2013 were identified.
Results: A significantly faster and more extensive volume
increase of the standardized future liver remnant (sFLR) was
observed following the ALPPS procedure (89%), when com-
pared to PVE (52%). All 10 ALPPS patients completed the
two staged hepatectomy compared to only 11/15 in the PVE
group. There was no significant difference in the total
number of complications (p > 0.99) or severe complications
(≥IIIB) (p = 0.84) in the two groups. No deaths were
observed in the ALPPS group. Mean time off chemotherapy
was shorter 130.25 ± 31.4 in the ALPPS group compared to
213.4 ± days in the PVE group (p < 0.001). Mean time until
return to chemotherapy was 70.8 ± 8.1 days in the ALPPS
group and 93 ± 45.9days in the PVE group (p = 0.15). At
time of maximal follow-up in patients who completed the
planned curative resection, recurrence occurred in 10% of
patients in the ALPPS group and 36% of patients in the PVE
group (p = 0.16).
Conclusions: In appropriate selected patients the ALPPS
procedure can be performed with low mortality and morbid-
ity rates that are similar to those demonstrated with PVE. The
ALPPS approach is a potential valid option to enable resec-
tion in patients with CRLM previously considered
unresectable by standard techniques, offering several advan-
tages over PVE.
O-G.14 COMPARISON OF SURVIVAL AND
TOLERABILITY OF LIVER
RADIOEMBOLIZATION IN ELDERLY VS.
YOUNGER PATIENTS WITH
METASTATIC COLORECTAL CANCER
S. Tohme1, G. Nace1, D. Sukato1, J. Steele1, A. Zajko2,
N. Amesur2, J. W. Marsh1, D. Geller1 and A. Tsung1
1Department Of Surgery, University Of Pittsburgh School
Of Medicine, Pittsburgh, PA; 2Department Of Radiology,
University Of Pittsburgh School Of Medicine, Pittsburgh,
PA
Aim: To evaluate the outcomes among elderly (≥70 years)
and younger patients (<70 years) with liver-dominant
metastatic colorectal cancer (mCRC) who received
radioembolization as a salvage therapy.
Methods: A retrospective review of 107 consecutive
patients with unresectable mCRC who were treated with
radioembolization after failing first and second line chemo-
therapy. Demographics, treatment doses, biochemical and
radiologic response, toxicities, and survival were examined.
Results: Between 8/2002 and 4/2012, 44 elderly and 63
younger patients received radioembolization. Patients in both
groups had similar previous extensive chemotherapy and
liver-directed interventions. Using RECIST criteria, either
stable or partial response was seen in 65.8% of the younger
vs. 76.5% of the elderly patients (p = 0.357).
Radioembolization was equally well tolerated in both groups
and common procedure-related adverse events were pre-
dominantly grade 1–2 and of short duration. No significant
difference was found with regard to overall median survival
between younger (8.4months; 95% CI = 6.23–10.63) or
elderly patients (8months; 95% CI = 4.51–11.43, p = 0.35).
The presence of extrahepatic disease at the time of
radioembolization was associated with a significantly worse
median survival in both groups. A significant improved sur-
vival was seen in elderly patient whose CEA responded to
radioembolization compared to those who didn’t (13.6
months; 95% CI = 2.37–24.77 vs. 3.0months; 95%
CI = 2.76–3.24, p = 0.01).
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Conclusion: Radioembolization appears to be as well toler-
ated and effective for the elderly as it is for younger patients
with mCRC. Age alone should not be a discriminating factor
for the management of mCRC patients.
O-G.15 WHAT IS THE CURRENT ROLE
OF PERIHEPATIC DRAIN (PD)
PLACEMENT IN LIVER SURGERY? A
PROSPECTIVE ANALYSIS
J. M. Butte, J. Grendar, O. Bathe, F. Sutherland, C. G. Ball
and E. Dixon
Foothills Medical Centre, , Calgary, ALBERTA
Background: The standard use of PD in hepatic surgery is
controversial and mainly supported by retrospective
data.This study evaluates the role of PD in liver surgery.
Methods: All patients included in a previous, randomized
trial(RCT) that evaluated the role of mucomyst in liver resec-
tion were analyzed to determine the association between PD
placement, postoperative complications (PC), and their
initial treatment.A multivariate analysis (MVA) determined
predictor factors of PC. A p < 0.05 was considered
significant.
Results: One hundred-ninety nine patients were analyzed
[119 (60%) males; median age = 60 years (22–84)]. The
majority of patients had colorectal liver metastasis (n = 114,
57%). PD (n = 87, 44%) were used most commonly in
patients that had preoperative biliary instrumentation
(p = 0.023), intraoperative bleeding (p = 0.01), Pringle’s
maneuver (p < 0.001), and a more extensive resection
(p = 0.001). Seventy-seven (39%) patients had a PC, which
was associated with preoperative biliary instrumentation
(p = 0.048), extent of resection (p = 0.002), and postopera-
tive blood transfusions (p = 0.001). Patients with PD had a
slightly higher rate of PC (46 vs. 33%) (p = 0.078) and a
significant number of high grade PC (25% vs. 12%,
p = 0.008). Nineteen patients(9.5%) developed a postopera-
tive collection, with a similar incidence in those with (n = 10,
11.5%) and without (n = 9, 8%) PD, p = 0.47. Seven (8%)
patients treated with and 9 (8%) treated without an PD
needed a second drain after surgery (p = 1).Resection of ≥3
segment was the only factor found to be associated with PC
(OR = 2, p = 0.025, 95% CI 1.1–3.7) in the MVA.
Conclusions: Despite preferential PD use in patients with
more complex tumors, they did not decrease the rate of PC,
postoperative collections, and the need for the placement of a
percutaneous postoperative drain.PD should be reserved for
exceptional circumstances in liver surgery.
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